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orporations are increasingly 
expected to behave ethically 
and to make their operations 
as transparent as possible. This is 
especially the case for the bioscience 
industry (biotechnology and 
pharmaceutical ﬁ  rms). These ﬁ  rms 
deal with a commodity like no other: 
our health and well-being. They also 
engage in research that manipulates 
the basic building blocks of life and 
challenges common understandings 
of the boundaries between humans 
and animals, the treatment of disease 
versus the enhancement of healthy 
lives [1], and when life begins or ends. 
To address these complex challenges, 
bioscience corporations have begun 
to implement a range of practices to 
address the scope of ethical questions 
that their operations pose. In a new 
Policy Forum article published in   PLoS 
Medicine  , Jocelyn Mackie and colleagues 
describe the variety of mechanisms that 
bioscience ﬁ  rms have put in place to 
address the ethical issues confronting 
them [2]. 
  The  Methodology
    Based on more than 100 interviews with 
executives and senior managers from 
13 ﬁ  rms, the authors sought to ﬁ  nd 
out what these professionals had to say 
about what their companies are doing 
to promote ethical behaviour. To date, 
there has been relatively little empirical 
research on this topic. As such, it is a 
timely piece. 
    The authors draw upon a larger 
study, in which detailed case studies 
were developed for each ﬁ  rm, including 
the ethical challenges that the ﬁ  rms 
faced and the mechanisms used to 
address them. The ﬁ  rms selected for 
analysis were chosen because they were 
known to be developing innovative 
approaches to dealing with ethical 
issues. They were further selected to 
represent the diversity of this industrial 
sector and to account for variations in 
ﬁ  rm size and location. In the paper, 
the authors seek to draw comparatively 
upon the case studies they developed 
to highlight the range and variety 
of mechanisms adopted by ﬁ  rms to 
address ethical issues.
    Approaches Used by Firms to 
Encourage Ethical Behaviour
    Based on the analysis presented, ﬁ  rms 
of all sizes and in different market 
niches are using a variety of approaches 
to encourage ethical behaviour. First 
of all, executives are promoting ethics 
as part of a ﬁ  rm’s core values. There is 
also evidence of specialisation: larger 
ﬁ  rms are able to create dedicated 
departments, while smaller ﬁ  rms 
are incorporating ethics into the 
responsibilities of senior managers. 
    The companies studied have further 
retooled their organisational structures 
with ethics in mind: ethics shaped 
their hiring and staff performance 
evaluations, employees in some 
ﬁ  rms were given ethics training, and 
visual and oral reminders were being 
used in the workplace to reinforce 
an organisation’s commitment to 
its ethical values. In instances where 
internal expertise was lacking, external 
consultants were brought in or 
independent ethics advisory boards 
were created to provide guidance and 
advice. Regardless of size, most of 
the ﬁ  rms studied were engaging with 
a range of stakeholders—whether it 
be reshaping their relationships with 
suppliers to maintain high ethical 
standards, consulting with a local 
community, inviting activists to visit 
laboratory facilities, or launching 
corporate philanthropy programmes 
in Africa. Lastly, ﬁ  rms are beginning to 
develop measures for evaluating and 
reporting their ethical behaviour.
  The  Implications
    This study demonstrates that (at least 
for a selective range of ﬁ  rms in the 
bioscience industry) some corporations 
have started to believe that the types of 
relationships they have with patients, 
carers, families, physicians, activists, 
partners, suppliers, regulators, and 
the public are an essential element 
of corporate ﬁ  nancial and social 
viability. Considering that some of 
the ﬁ  rms studied do not seem to have 
any products on the market, current 
and anticipated ethical concerns are 
shaping their corporate practices and 
bottom lines in the here and now. 
This paper also provides evidence of 
how ethical decision making is not an 
entirely abstract philosophical exercise: 
ethics has to be embedded in a range 
of social practices and relationships 
that need to be continually cultivated 
and reinforced if they are to be 
effective.
    Lastly, it can be extrapolated that 
ethics is an asset that ﬁ  rms can trade 
upon. Firms are considering ethics 
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as central not only to their research 
activities and the dissemination of 
their products to consumers, but also 
to the reputation and branding of the 
company itself. Of course, ethics, like 
any other asset, has multiple values. 
Ethics can be used by ﬁ  rms not only 
to shape their decisions, but to aid 
corporate public relations campaigns. 
No doubt, the multifaceted character 
of corporate ethics programmes can 
lead to outbreaks of scepticism amongst 
bioethicists and the public. 
  Unresolved  Questions
    A question that was left unresolved 
by the authors was how effective 
these mechanisms have been at 
accomplishing their objectives. Whilst 
ﬁ  rms may not yet be evaluating the 
actual impact of these mechanisms, it 
is imperative for bioethicists studying 
these mechanisms to discuss their 
relative merits and disadvantages. 
Better yet would be an evaluation of 
how ethical these companies actually 
are. In a similar vein, we need to 
know more about how and to what 
extent the mechanisms adopted 
by ﬁ  rms inﬂ  uenced their research, 
investment, or marketing decisions. 
Finding out about such inﬂ  uence will 
require further empirical analysis and 
a willingness on the part of executives 
in the bioscience industry to let 
researchers not only interview them 
but also observe what goes on in their 
boardrooms. This type of transparency 
would facilitate the investigation of 
what kinds of problems do and do not 
get deﬁ  ned as being ethical and the 
organisational processes that shape 
ﬁ  rm behaviour. Lastly, it is important to 
emphasise that ﬁ  rms, like individuals, 
do not live in isolation. We need to 
pay greater attention to the broader 
political, economic, and social context 
that has encouraged ﬁ  rms to develop 
mechanisms to address ethical issues, as 
well as the role of industry organisations 
and professional associations 
in facilitating the uptake and 
dissemination of these mechanisms.
    It will be important to study 
bioscience ﬁ  rms as they start 
to incorporate ethics into their 
organisational practices and into the 
very products they develop through 
their research decisions. To date, this 
subject area has not been extensively 
explored by bioethicists. As more 
aspects of our health and illness are 
embraced by the bioscience industry, 
the ethical issues surrounding 
industry’s actions will become an area 
that is ripe for analysis. 
    The Relationship between Ethicists 
and Corporations
    A question that this paper opens up 
for further analysis and debate, given 
that ﬁ  rms are starting to integrate 
ethics into their organisational 
practices, is how and through what 
forms bioethicists should relate to 
corporations. At the present time, 
there seem to be two dominant forms. 
One form appeals to the values long 
cherished in academe: independence, 
critical scholarship, credibility, and 
integrity [3,4]. The other form appeals 
to the values to be gained by consulting 
for industry: corporate or policy 
relevance, alongside honoraria, salaries, 
and grants [5]. Presently, bioethics 
seems to be at an impasse over what 
form to adopt. 
    Perhaps the lessons to be learned 
come from the bioscience industry 
itself. As ﬁ  rms have started to 
reformulate their organisational 
forms and modes of conduct in 
relation to changing socioeconomic 
circumstances, perhaps it is an 
opportune moment for bioethicists 
to rethink the subjects they choose 
to study and how bioethics engages 
with its various stakeholders. Just as 
scientists have created new theories 
and techniques to investigate the 
phenomena of life, bioethicists need 
to develop new concepts and tools for 
proposing how we should individually 
and collectively relate to one another 
in a manner that is capable of dealing 
with the dilemmas that will be posed 
by the provision of health in the 21st 
century.   
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